Analytical and Clinical Validation of Action PharmaKitDx: A Comprehensive NGS Panel for the Identification of Pharmacogenetic Variants in Diverse Populations
Year: 2026
Type: article
Abstract: Background/Objectives: Pharmacogenomics (PGx) enables personalized therapy by identifying genetic variants that influence drug response. Despite the advantages of next-generation sequencing (NGS), few clinically validated, guideline-aligned panels comprehensively detect common, rare, and structurally complex pharmacogenetic variants. Methods: We developed and analytically validated Action PharmaKitDx, a targeted NGS panel covering 335 pharmacogenes, including all priority genes recommended by CPIC, DPWG, and CPNDS. Performance was assessed using Coriell HapMap and GeT-RM reference materials across multiple library preparation workflows and Illumina platforms. Clinical feasibility was evaluated in 41 patient samples from diverse specialties. Results were compared with established reference methods, including PCR-based assays, STR analysis, Sanger sequencing, and whole-exome sequencing. Results: More than 99% of target bases achieved ≥30× coverage. Analytical accuracy, sensitivity, specificity, and positive predictive value exceeded 99.3%, with repeatability and reproducibility >99.7%. Concordance with GeT-RM haplotypes reached 98% after star-allele harmonization. The panel accurately detected complex variants, including CYP2D6 copy-number changes and hybrid alleles. Full concordance with prior genotyping was observed in clinical samples. Beyond the initial testing indication, each sample harbored a mean of six actionable variants (range 2–10). Thirty-six rare (minor allele frequency <1%) potentially actionable variants were additionally identified. Conclusions: Action PharmaKitDx demonstrates high analytical performance and broad clinical applicability, supporting its implementation as a scalable solution for comprehensive pharmacogenetic testing and precision prescribing.
Source: Pharmaceuticals
DOI: 10.3390/ph19040568
Authors: Luis Ramudo-Cela, Marta Izquierdo-García, María Dolores-Sequedo, Vicente Cubells-Perez, Sara Bernal Noguera, Pau Riera Armengol, Adriana Lasa Laborda, Laura Torres-Juan, Victor José Asensio, Iciar Martínez-López, Antonia Obrador de Hevia, Matías Morín, Miguel Ángel Moreno-Pelayo, Greta Carmona-Antoñanzas, Javier Porta Pelayo
Institutions: Universidade da Coruña, Complexo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica de A Coruña, Hospital de Sant Pau, Institut de Recerca Sant Pau, Health Research Institute of the Balearic Islands, Hospital Universitario Son Espases, Centre for Biomedical Network Research on Rare Diseases, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,499
Award: G1900342659
OpenAlex ID: W7148337111
